Increasing occurrence of atypical femoral fractures associated with bisphosphonate use
- PMID: 22732749
- DOI: 10.1001/archinternmed.2012.1796
Increasing occurrence of atypical femoral fractures associated with bisphosphonate use
Abstract
Background: Current evidence suggests that there is an association between bisphosphonate therapy and atypical femoral fractures, but the extent of this risk remains unclear.
Methods: Between 1999 and 2010, a total of 477 patients 50 years and older were hospitalized with a subtrochanteric or femoral shaft fracture at a single university medical center. Admission radiographs and medical and treatment records were examined, and patients were classified as having atypical or classic femoral fractures. A random sample of 200 healthy individuals without femoral fracture were also identified. Multivariate logistic regression was used to assess the association of bisphosphonate use and atypical femoral fracture, and the incidence rates of each type of fracture over time were calculated.
Results: Thirty-nine patients with atypical fractures and 438 patients with classic fractures were identified. Of the patients with atypical fractures, 32 (82.1%) had been treated with bisphosphonates compared with 28 (6.4%) in the classic fractures group (odds ratios [OR], 66.9; 95% CI, 27.1-165.1) and 11.5% in the group without fracture (OR, 35.2; 95% CI, 13.9-88.8). Bisphosphonate use was associated with a 47% reduction in risk of classic fracture (OR, 0.5; 95% CI, 0.3-0.9). Considering the duration of use, the ORs (95% CIs) for atypical fractures were 35.1 (10.0-123.6) for less than 2 years, 46.9 (14.2-154.4) for 2 to 5 years, 117.1 (34.2-401.7) for 5 to 9 years, and 175.7 (30.0-1027.6) for more than 9 years compared with no use. A contralateral fracture occurred in 28.2% of atypical cases and in 0.9% of classic cases (OR, 42.6; 95% CI, 12.8-142.4). The incidence rate of atypical fractures was low (32 cases per million person-years) and increased by 10.7% per year on average.
Conclusions: Atypical femoral fractures were associated with bisphosphonate use; longer duration of treatment resulted in augmented risk. The incidence of atypical fractures increased over a 12-year period, but the absolute number of such fractures is very small.
Comment in
-
Atypical femoral fracture risk in patients treated with bisphosphonates.Arch Intern Med. 2012 Jun 25;172(12):936-7. doi: 10.1001/archinternmed.2012.1827. Arch Intern Med. 2012. PMID: 22732750 Free PMC article. No abstract available.
Similar articles
-
Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women.JAMA. 2011 Feb 23;305(8):783-9. doi: 10.1001/jama.2011.190. JAMA. 2011. PMID: 21343577
-
Risk of atypical femoral fracture during and after bisphosphonate use.Acta Orthop. 2015 Feb;86(1):100-7. doi: 10.3109/17453674.2015.1004149. Epub 2015 Jan 13. Acta Orthop. 2015. PMID: 25582459 Free PMC article.
-
Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy.Bone. 2012 Sep;51(3):524-7. doi: 10.1016/j.bone.2012.05.010. Epub 2012 May 23. Bone. 2012. PMID: 22634175
-
Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates.Curr Osteoporos Rep. 2010 Mar;8(1):34-9. doi: 10.1007/s11914-010-0007-2. Curr Osteoporos Rep. 2010. PMID: 20425089 Review.
-
[Atypical femoral fracture associated with the use of bisphosphonates, an adverse drug reaction not to be missed].Rev Med Suisse. 2012 Jun 6;8(344):1238-42. Rev Med Suisse. 2012. PMID: 22730621 Review. French.
Cited by
-
Sequential treatment from bisphosphonate to denosumab improves lumbar spine bone mineral density in postmenopausal osteoporosis patients: A meta-analysis of randomized controlled trials.Medicine (Baltimore). 2024 Nov 15;103(46):e40594. doi: 10.1097/MD.0000000000040594. Medicine (Baltimore). 2024. PMID: 39560527 Free PMC article.
-
Atypical Periprosthetic Femoral Fracture Might be Considered a Distinct Subtype of Atypical Femoral Fracture: A Retrospective Study.Orthop Surg. 2024 Oct;16(10):2454-2463. doi: 10.1111/os.14174. Epub 2024 Jul 28. Orthop Surg. 2024. PMID: 39072929 Free PMC article.
-
Teriparatide Does not Have Beneficial Effects on Bone Healing in Complete Atypical Femur Fractures.Calcif Tissue Int. 2024 Aug;115(2):169-173. doi: 10.1007/s00223-024-01244-x. Epub 2024 Jun 21. Calcif Tissue Int. 2024. PMID: 38907093
-
Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.Cochrane Database Syst Rev. 2024 Apr 9;4(4):CD003376. doi: 10.1002/14651858.CD003376.pub4. Cochrane Database Syst Rev. 2024. PMID: 38591743 Review.
-
Differences in femoral fracture localizations in men and women in Switzerland between 1998 and 2021-reversal of the secular trend?Osteoporos Int. 2024 May;35(5):893-902. doi: 10.1007/s00198-024-07016-5. Epub 2024 Feb 24. Osteoporos Int. 2024. PMID: 38396306 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
